Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.195,94
-0,16%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ionis Pharmaceuticals Inc (IONS) Ionis Pharmaceuticals Inc (IONS) Notizie

Ionis Pharmaceuticals Inc

IONS
38,95
-0,92 (-2,31%)
08 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
31/5/202413:15EDGAR2Form 8-K - Current report
31/5/202413:00PRNUSIonis presents positive results from OASIS-HAE and OASISplus..
28/5/202413:00PRNUSIonis to hold donidalorsen Phase 3 data webcast
23/5/202413:00PRNUSNew data from the Phase 3 NEURO-TTRansform study evaluating..
16/5/202413:30GLOBEBiogen and Ionis Announce Topline Phase 1/2 Study Results of..
16/5/202413:30PRNUSIonis and Biogen Announce Topline Phase 1/2 Study Results of..
16/5/202413:00PRNUSIonis announces positive topline results from Phase 1/2a..
15/5/202413:05PRNUSIonis to host 2024 virtual Annual Meeting of Stockholders
13/5/202423:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202421:55EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202417:15EDGAR2Form 8-K - Current report
07/5/202413:00PRNUSIonis reports first quarter 2024 financial results
25/4/202413:00PRNUSIonis Publishes 2023 Corporate Responsibility Report
23/4/202413:05PRNUSIonis to hold first quarter 2024 financial results webcast
07/4/202415:48PRNUSIonis presents positive results from Phase 3 Balance study..
01/4/202413:05PRNUSIonis to present at upcoming investor conferences
28/3/202412:05PRNUSIonis to hold olezarsen Phase 3 data webcast
25/3/202413:18PRNUSPositive olezarsen Phase 3 data in familial chylomicronemia..
13/3/202412:00PRNUSIonis announces positive results from Phase 2 study of..
06/3/202413:30GLOBENew Biomarker Data Add Further Evidence Supporting the..
05/3/202401:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202401:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202401:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202401:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202401:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:10EDGAR2Form 8-K - Current report
29/2/202415:05PRNUSIonis announces new chief global product strategy officer to..
28/2/202413:05PRNUSIonis to present at upcoming investor conferences
21/2/202417:17EDGAR2Form 8-K - Current report
21/2/202413:00PRNUSIonis reports fourth quarter and full year 2023 financial..
20/2/202416:39EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
17/2/202401:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:34EDGAR2Form 144 - Report of proposed sale of securities
15/2/202413:00PRNUSOlezarsen receives Orphan Drug designation from U.S. FDA for..
14/2/202416:04EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/2/202412:09EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202413:00PRNUSEplontersen granted U.S. FDA Fast Track designation for..
07/2/202413:05PRNUSIonis to hold fourth quarter and full year 2023 financial..
03/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:34EDGAR2Form 144 - Report of proposed sale of securities
02/2/202423:31EDGAR2Form 144 - Report of proposed sale of securities
02/2/202423:30EDGAR2Form 144 - Report of proposed sale of securities
Apertura: 39,59 Min: 38,77 Max: 39,635
Chiusura: 39,87

La tua Cronologia

NASDAQ
IONS
Ionis Pharmaceuticals
BIT
UC5EZP
Unicredit Bank
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network